Alexandre Sostelly

441 total citations
27 papers, 209 citations indexed

About

Alexandre Sostelly is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Alexandre Sostelly has authored 27 papers receiving a total of 209 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 11 papers in Immunology and 7 papers in Oncology. Recurrent topics in Alexandre Sostelly's work include Blood groups and transfusion (12 papers), Complement system in diseases (9 papers) and Hemoglobinopathies and Related Disorders (5 papers). Alexandre Sostelly is often cited by papers focused on Blood groups and transfusion (12 papers), Complement system in diseases (9 papers) and Hemoglobinopathies and Related Disorders (5 papers). Alexandre Sostelly collaborates with scholars based in Switzerland, United States and France. Alexandre Sostelly's co-authors include François Mercier, Jeroen Elassaiss‐Schaap, Malidi Ahamadi, Andreas Lindauer, JA Stone, Kapil Mayawala, Rik de Greef, Tomoko Freshwater, Mats Jirstrand and Christiane Amendt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Alexandre Sostelly

27 papers receiving 209 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alexandre Sostelly Switzerland	8	87	68	42	32	30	27	209
Anson K. Abraham United States	12	138 1.6×	110 1.6×	152 3.6×	29 0.9×	17 0.6×	17	353
David Rageot France	10	135 1.6×	108 1.6×	66 1.6×	49 1.5×	9 0.3×	18	398
Carina Forsare Sweden	10	139 1.6×	54 0.8×	89 2.1×	76 2.4×	24 0.8×	14	272
R. Neumann Germany	10	125 1.4×	19 0.3×	96 2.3×	40 1.3×	91 3.0×	20	326
Jin Shu China	9	39 0.4×	52 0.8×	111 2.6×	14 0.4×	64 2.1×	18	285
Roy Elias United States	11	191 2.2×	56 0.8×	165 3.9×	141 4.4×	28 0.9×	40	411
Nathalie Beaufils France	9	36 0.4×	18 0.3×	84 2.0×	24 0.8×	37 1.2×	16	215
Millie Wang United Kingdom	7	38 0.4×	74 1.1×	34 0.8×	88 2.8×	42 1.4×	11	269
Kohei Yamasaki Japan	7	25 0.3×	65 1.0×	132 3.1×	63 2.0×	58 1.9×	9	304
Л. П. Менделеева Russia	7	93 1.1×	21 0.3×	155 3.7×	38 1.2×	154 5.1×	81	333

Countries citing papers authored by Alexandre Sostelly

Since Specialization

Citations

This map shows the geographic impact of Alexandre Sostelly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexandre Sostelly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexandre Sostelly more than expected).

Fields of papers citing papers by Alexandre Sostelly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexandre Sostelly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexandre Sostelly. The network helps show where Alexandre Sostelly may publish in the future.

Co-authorship network of co-authors of Alexandre Sostelly

This figure shows the co-authorship network connecting the top 25 collaborators of Alexandre Sostelly. A scholar is included among the top collaborators of Alexandre Sostelly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexandre Sostelly. Alexandre Sostelly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cohen, Sharon, Simon Ducharme, Jared R. Brosch, et al.. (2024). Single ascending dose results from an ongoing Phase 1 study of mivelsiran (ALN‐APP), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer’s disease. Alzheimer s & Dementia. 20(S6). 4 indexed citations

Röth, Alexander, Satoshi Ichikawa, Yoshikazu Ito, et al.. (2023). Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long‐term results from the phase I/II COMPOSER trial. European Journal Of Haematology. 111(2). 300–310. 10 indexed citations

Cohen, Sharon, Simon Ducharme, Jared R. Brosch, et al.. (2023). Interim phase 1 part A results for ALN‐APP, the first investigational RNAi therapeutic in development for Alzheimer’s disease. Alzheimer s & Dementia. 19(S24). e082650–e082650. 8 indexed citations

Liu, Hui, Linghui Xia, Jianyu Weng, et al.. (2023). Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor‐naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single‐arm study. American Journal of Hematology. 98(9). 1407–1414. 20 indexed citations

Micallef, Sandrine, Alexandre Sostelly, Jiawen Zhu, Paul Baverel, & François Mercier. (2022). Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial. Contemporary Clinical Trials Communications. 26. 100901–100901. 7 indexed citations

Bartolucci, Pablo, Kenneth I. Ataga, Michael U. Callaghan, et al.. (2022). P119: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1B CROSSWALK-A TRIAL EVALUATING THE SAFETY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD). HemaSphere. 6. 27–27. 2 indexed citations

Zhang, Yuchen, et al.. (2022). Pharmacokinetic Characterization and Exposure-Response Relationship of Crovalimab in the COMPOSER and COMMODORE 3 Trials of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood. 140(Supplement 1). 2918–2920. 2 indexed citations

Bartolucci, Pablo, Kenneth I. Ataga, Michael U. Callaghan, et al.. (2021). Trial in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase Ib CROSSWALK-a Trial Evaluating the Safety of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOEs) in Patients with Sickle Cell Disease (SCD). Blood. 138(Supplement 1). 3108–3108. 6 indexed citations

Kulasekararaj, Austin, Antonio M. Risitano, Guangsheng He, et al.. (2021). Two Currently Recruiting Randomized Phase III Trials: COMMODORE 1 and 2 Evaluating Crovalimab Vs Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Current Anti-Complement Therapy. Blood. 138(Supplement 1). 4313–4313. 1 indexed citations

10.

Risitano, Antonio M., Alexander Röth, Austin Kulasekararaj, et al.. (2020). Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 1 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Complement Inhibitors. Blood. 136(Supplement 1). 43–44. 1 indexed citations

11.

Kulasekararaj, Austin, Guangsheng He, Talha Munir, et al.. (2020). Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 2 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Not Previously Treated with Complement Inhibitors. Blood. 136(Supplement 1). 34–34. 1 indexed citations

12.

Latour, Régis Peffault de, Simona Sica, Jules Hernández‐Sánchez, et al.. (2020). COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood. 136(Supplement 1). 6–7. 2 indexed citations

13.

Sostelly, Alexandre & François Mercier. (2019). Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab. Clinical Medicine Insights Oncology. 13. 2281547815–2281547815. 8 indexed citations

14.

Sostelly, Alexandre, Antoine Soubret, Christoph Bucher, et al.. (2019). Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes. Blood. 134(Supplement_1). 1227–1227. 2 indexed citations

15.

Sostelly, Alexandre, Guillemette Duchâteau-Nguyen, Claire Petry, et al.. (2019). OP0224 RESULTS OF A PHASE 2 STUDY OF RG6125, AN ANTI-CADHERIN-11 MONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO ANTI-TNFALPHA THERAPY. Annals of the Rheumatic Diseases. 78. 189–189. 17 indexed citations

16.

Sostelly, Alexandre, et al.. (2018). Abstract 1643: Leveraging tumor size and time to death from bevacizumab (BEV) historical data to predict overall survival in ovarian cancer patients treated with vanucizumab (VAN). Cancer Research. 78(13_Supplement). 1643–1643. 2 indexed citations

17.

Almquist, J.O., Mats Jirstrand, Alexandre Sostelly, et al.. (2016). Tumor Static Concentration Curves in Combination Therapy. The AAPS Journal. 19(2). 456–467. 17 indexed citations

18.

Elassaiss‐Schaap, Jeroen, Andreas Lindauer, Alexandre Sostelly, et al.. (2016). Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma. CPT Pharmacometrics & Systems Pharmacology. 6(1). 29–39. 65 indexed citations

19.

Sostelly, Alexandre, Émilie Hénin, L. Chauvenet, et al.. (2012). Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO. Journal of Geriatric Oncology. 4(1). 48–57. 10 indexed citations

20.

Sostelly, Alexandre, Claire Falandry, Éric Pujade-Lauraine, Gilles Freyer, & Michel Tod. (2011). Predicting chemotherapy-induced hematotoxicity elderly patients with metastatic breast cancer treated by pegylated liposomal doxorubicin (PLD): A population-based analysis on data coming from the DOGMES phase II GINECO study.. Journal of Clinical Oncology. 29(15_suppl). e19740–e19740. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact